论文部分内容阅读
目的:探讨CCNB1在卵巢癌诊断和预后判断的作用。方法:通过Oncomine数据库分析并提取组织RNA,Real-time PCR法检测CCNB1在卵巢癌组织中的表达。通过在线数据库及分析工具“the Kaplan Meier plotter”(KM plotter)数据库的应用发掘CCNB1的预后价值。结果:Oncomine数据库中共有18个研究结果涉及正常卵巢组织和卵巢癌组织中的CCNB1的表达情况,全部显示CCNB1在卵巢癌中表达增高。本研究对9对配对的卵巢癌及其癌旁组织进行Real-time PCR,得到相同结果。在KM plotter数据库中的分析显示:无论是无进展生存期(PFS)或总生存期(OS),CCNB1 mRNA水平越高,卵巢癌患者的预后越差(HR>1,P<0.05)。且CCNB1 mRNA高水平在早于2期(包括2期)卵巢癌患者中提示预后较差,在晚于3期(包括3期)患者中CCNB1 mRNA水平与预后无明显相关性。结论:CCNB1在卵巢癌组织中表达升高,可作为提示预后差的卵巢癌的分子标记物。
Objective: To investigate the role of CCNB1 in the diagnosis and prognosis of ovarian cancer. Methods: Tissue RNA was analyzed by Oncomine database and the expression of CCNB1 was detected by Real-time PCR in ovarian cancer. The prognostic value of CCNB1 was explored through the use of an online database and analysis tool “the Kaplan Meier plotter” (KM plotter) database. RESULTS: A total of 18 studies in the Oncomine database involved the expression of CCNB1 in normal ovarian tissues and ovarian cancer tissues, all of which showed that CCNB1 expression was increased in ovarian cancer. In this study, 9 pairs of paired ovarian cancer and its adjacent tissues were subjected to Real-time PCR to obtain the same result. Analysis in the KM plotter database showed that the prognosis of patients with ovarian cancer was poorer (P> 0.05) for CCNB1 mRNA levels, both in progression-free survival (PFS) and overall survival (OS). And the high level of CCNB1 mRNA in early stage 2 (including stage 2) patients with ovarian cancer prompted a poor prognosis, CCNB1 mRNA level in late stage 3 (including stage 3) and prognosis was not significantly correlated. Conclusion: The expression of CCNB1 is increased in ovarian cancer tissues and can be used as a molecular marker of ovarian cancer with poor prognosis.